Antisense Oligonucleotides Targeting IRF4 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches are unable to effectively target Interferon Regulatory Factor 4 (IRF4), which is implicated in various cancers and considered an undruggable target, leading to challenges in treating hematological malignancies and other lymphomas.
Innovation Solution
Development of potent and tolerable compounds and compositions, specifically antisense oligonucleotides that inhibit IRF4 expression by targeting IRF4 nucleic acids with modified oligonucleotides, including those with 2′-O-methoxyethyl modifications and phosphorothioate linkages, to reduce IRF4 levels in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic approaches are used, then treatment of cancers with IRF4 involvement is attempted, but IRF4 is considered an undruggable target and treatment effectiveness is poor
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to IRF4 mRNA to prevent translation, rather than attempting to directly inhibit the IRF4 protein. This intermediary approach allows targeting of an 'undruggable' transcription factor through its RNA transcript, resolving the contradiction between treatment effectiveness and target druggability
Solution Approach 2:
The patent replaces conventional small molecule drug mechanisms with nucleic acid-based antisense mechanisms. Instead of using small molecules that attempt to bind to protein targets, the invention uses modified oligonucleotides that bind to complementary RNA sequences through base pairing, substituting a different molecular recognition mechanism that is effective against transcription factors
2Reliability
If antisense oligonucleotides with modifications are used to inhibit IRF4 expression, then IRF4 levels are reduced in cancer cells, but the complexity of the compound structure increases
Solution Approach 1:
The patent applies modifications locally at specific positions within the oligonucleotide sequence rather than uniformly throughout. For example, 2'-O-methoxyethyl modifications are applied at specific nucleotide positions to enhance stability and binding affinity while maintaining sequence-specific complementarity to IRF4 mRNA, thus achieving effective inhibition with controlled structural complexity
Solution Approach 2:
The patent creates composite oligonucleotide structures combining different nucleotide types (modified and unmodified) and different backbone chemistries (phosphorothioate, phosphodiester) within a single molecule. This composite approach allows the molecule to exhibit multiple properties: high affinity binding, enhanced nuclease resistance, and improved cellular uptake, while the modular nature manages the complexity through systematic design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit IRF4 expression, potentially slowing cancer progression and treating cancers associated with IRF4, such as multiple myeloma and non-Hodgkin's lymphoma, by specifically targeting IRF4 in cancer cells without significant side effects.
Implementation Method 1
contacting the cell with a compound, wherein the compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising any one of SEQ ID NOs: 2021, 560, 559, 1330, 1540, or 3303, thereby inhibiting expression of IRF4 in the cell
Implementation Method 2
Development of potent and tolerable compounds and compositions, specifically antisense oligonucleotides that inhibit IRF4 expression by targeting IRF4 nucleic acids with modified oligonucleotides, including those with 2′-O-methoxyethyl modifications and phosphorothioate linkages
Data Source
AI summary
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.